Amneal EVP Daly sells 216,613 company shares

Amneal Pharmaceuticals, Inc. executive Jason B. Daly, EVP and Chief Legal Officer, reported selling a total of 216,613 shares of Class A Common Stock in two open-market or private transactions.

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. executive Jason B. Daly, EVP and Chief Legal Officer, reported selling a total of 216,613 shares of Class A Common Stock in two open-market or private transactions. On 2026-08-12 he sold 210,000 shares at $17.40 per share (weighted average, with individual trades between $17.25 and $17.67). On 2026-08-11 he sold 6,613 shares at $17.70 per share (weighted average, with individual trades between $17.65 and $17.73). The Rule 10b5-1 checkbox was not marked as being pursuant to a trading plan, and post-transaction share holdings were not reported in this form.

Insider Trade Summary

Net Seller: 216,613 shares

Net Sell 2 txns

Insider Daly Jason B.

Role EVP, Chief Legal Officer

Sold 216,613 shs ($3.77M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F2	210,000	$17.40	$3.65M
Sale	Class A Common Stock F1	6,613	$17.70	$117K

Holdings After Transaction: Class A Common Stock — 35,171 shares (Direct)

Footnotes (2)

1. F1. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.65 to $17.73 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
2. F2. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

Key Figures

Total shares sold: 216,613 shares Shares sold on 2026-08-12: 210,000 shares at $17.40 per share Shares sold on 2026-08-11: 6,613 shares at $17.70 per share +1 more

4 metrics

Total shares sold 216,613 shares Aggregate of reported sales in August 2026

Shares sold on 2026-08-12 210,000 shares at $17.40 per share Open-market or private transaction, weighted average price with range $17.25–$17.67

Shares sold on 2026-08-11 6,613 shares at $17.70 per share Open-market or private transaction, weighted average price with range $17.65–$17.73

Sell transactions count 2 Number of non-derivative sale transactions reported

Key Terms

weighted average price, open market or private transaction, Rule 10b5-1

3 terms

weighted average price financial

"The price included in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

Rule 10b5-1 regulatory

"The document-level Rule 10b5-1 checkbox is not marked."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did AMRX executive Jason B. Daly report?

Jason B. Daly reported selling 216,613 shares of Amneal Pharmaceuticals Class A Common Stock in two transactions on 2026-08-11 and 2026-08-12, both coded as open-market or private sales.

At what prices did Jason B. Daly sell AMRX shares?

Daly sold 6,613 shares at a weighted average of $17.70 on 2026-08-11 and 210,000 shares at a weighted average of $17.40 on 2026-08-12, with trades executed within stated price ranges.

How many AMRX shares did Jason B. Daly sell in total?

The Form 4 reports that Daly sold a total of 216,613 shares of Amneal Pharmaceuticals Class A Common Stock across two transactions, according to the filing’s transaction summary section.

Were Jason B. Daly’s AMRX share sales under a Rule 10b5-1 plan?

The document-level Rule 10b5-1 checkbox is not marked, indicating these reported sales were not affirmed as made pursuant to a Rule 10b5-1 trading plan in this filing.

What price ranges applied to Jason B. Daly’s AMRX sales?

Footnotes state that the $17.70 weighted-average sale involved prices from $17.65–$17.73, and the $17.40 weighted-average sale involved prices from $17.25–$17.67 per share, inclusive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 04:22 PM Accepted by SEC EDGAR 08/13/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daly Jason B.

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/11/2026		S		6,613	D	$17.7(1)	245,171	D
Class A Common Stock	08/12/2026		S		210,000	D	$17.4(2)	35,171	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.65 to $17.73 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

2. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)